A medication is helpful if patients can both afford it and stick with it
Aging populations, sedentary lifestyles, and urbanization contribute to increasing rates of metabolic disorders, creating a larger target patient pool for GLP-1 therapies
doi: 10.1111/j.1439-0272.2009.01013.x 43 Martnez-SotoJCDomingoJCCordobillaBNicolsMFernndezLAlberoPet al
We also signed an out-licensing agreement with Ajanta Pharma to market our vertically integrated drug product, Semaglutide, in 26 countries across Africa, Middle East and Central Asia. Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group | Q3 FY26 Biocons cost edge here is structural
The breathlessness - its just goneWhereas before just going to the bathroom or kitchenId be puffing and panting. (P2, male, obesity)